Test Price
2,800 AED✅ Home Collection Available
RUNX2 Gene Cleidocranial Dysplasia Genetic Test in UAE
Executive Summary & Core Metrics
UAE-ISO Certified Genomic Precision
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (ISO 9001:2015, Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by certified genetic counselors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The RUNX2 Gene Cleidocranial Dysplasia Genetic Test is a comprehensive next-generation sequencing analysis that detects pathogenic variants in the RUNX2 gene responsible for cleidocranial dysplasia. This test is ideal for confirming a clinical diagnosis, assessing familial risk, and enabling personalized management strategies in the UAE.
| Feature | Our Test (RUNX2 NGS) | Closest Alternative (Sanger Single-Gene Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity, full gene coverage | Limited to predefined variants; may miss novel mutations |
| Method | Next Generation Sequencing (NGS) with bioinformatics validation | Sanger sequencing of select exons |
| Speed | 3–4 Weeks (reliable, clinically actionable reports) | 2–3 Weeks (but incomplete gene coverage) |
Physician Insight & Safety Protocols
"As a DHA-certified Consultant Medical Genetics, I understand the anxiety a genetic diagnosis can bring. This RUNX2 test offers definitive molecular confirmation, but results must always be correlated with clinical and radiological findings by your treating physician. Please remember, your healthcare team is your strongest ally in interpreting and acting upon these insights."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License: 9294403
Safety Advisory
⚠ Do not discontinue any prescribed medication without consulting your doctor.
If you experience sudden neurological symptoms (severe headache, seizures), signs of increased intracranial pressure (vomiting, vision changes), or acute severe bone pain, seek immediate emergency care irrespective of test status.
Exclusion Criteria
This test requires a clinical or family history suggestive of cleidocranial dysplasia. Genetic counseling (pre- and post-test) is mandatory. Parental consent must be documented for minors as per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability. Individuals aged under 18 must be accompanied by a legal guardian for sample collection.
Patient FAQ & Clinical Guidance
1. What is the RUNX2 gene test used for?
Snippet: This test identifies germline pathogenic variants in the RUNX2 gene causing cleidocranial dysplasia, enabling accurate diagnosis and family cascade screening. The comprehensive NGS panel examines the entire coding region, guiding specialists like clinical geneticists, orthopedic surgeons, and dentists in long-term management and genetic counseling for relatives.
2. How is the sample collected for this genetic test?
Snippet: Sample collection involves a simple blood draw, or submission of extracted DNA or a dried blood spot on an FTA card. Our team provides a hospital-grade home collection service using a cold-chain certified kit; a VIP phlebotomist visits your location between 8 AM and 11 PM, ensuring minimal discomfort and sample integrity.
3. What is the turnaround time and cost of the RUNX2 NGS test in UAE?
Snippet: Turnaround time is 3 to 4 weeks from sample receipt, priced at 2,800 AED inclusive of genetic counseling pre-test. This fixed price covers the entire NGS workflow, clinical report generation by DHA-licensed experts, and a telephonic post-guidance session to explain your results in simple language.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This test is conducted under the regulatory oversight of the Dubai Health Authority (DHA) Facility License No. 1143. Our laboratory, DNA Labs UAE, adheres to strict data protection standards as per Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
ISO Certification: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
Clinical & Logistical Metadata
| Test Name | RUNX2 Gene Cleidocranial Dysplasia Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Bioinformatics Validation |
| ICD-10-CM Code | Q75.8 |
| LOINC Code | 95758-9 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians